Secukinumab In Patients With Moderate to Severe Active, Chronic Plaque Psoriasis Who Have Failed on TNFα antaGoNists: A Clinical Trial EvalUating Treatment REsults
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms SIGNATURE
- Sponsors Novartis Pharmaceuticals
- 18 Oct 2019 Results (n=233) assessing Efficacy of secukinumab in patients with moderate/severe chronic plaque psoriasis published in the British Journal of Dermatology
- 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 21 Sep 2016 Status changed from active, no longer recruiting to completed.